HEMATOLOGY

The combination of belumosudil plus ruxolitinib demonstrated response and tolerability in patients with steroid-refractory or steroid-dependent chronic graft-vs-host disease.

Findings from an analysis of the REACH2 study, presented at the 2024 Transplantation & Cellular Therapy Meetings, showed that concomitant treatment with azoles does not impact the safety and efficacy of ruxolitinib for patients with acute graft-vs-host-disease.

A retrospective study of insurance claims showed patients received ruxolitinib mainly in the second or third line for chronic graft-vs-host disease, with dose adjustment used and no difference shown in time to discontinuation between adult and pediatric patients.

Ruxolitinib cream resulted in positive safety and efficacy findings among a small cohort of patients with cutaneous graft-vs-host disease vs placebo.

An orphan drug designation has been granted by the FDA for IO-202 as a treatment option for patients with chronic myelomonocytic leukemia.

The ruxolitinib and belumosudil combination demonstrated a 55% overall response rate in GVHD, suggesting synergy between inflammatory pathways. The combination was well-tolerated, delayed the need for other therapies.

Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.

Following the FDA clearance of an investigational new drug application, a phase 1 trial will evaluate KME-0584 for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

Raajit K. Rampal, MD, PhD, discusses some of the key takeaways from the 2023 American Society of Hematology Annual Meeting and what he believes holds promise for the space in 2024.

Magrolimab will no longer be in development as a treatment option for patients with hematologic malignancies.

Gary J. Schiller, MD, concludes with thoughts on the clinical implications of recent data presented at ASH 2023 on the myelodysplastic syndrome treatment landscape.

A hematologist/oncologist discusses a phase 1b/2 study investigating canakinumab in patients with myelodysplastic syndrome.

In the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.

Drs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.

An expert on MDS reviews the biomarker analysis and patient-reported outcomes from the COMMANDS study as well as long-term outcomes from the MEDALIST study.

Dr Schiller reviews data updates from the IMerge phase 3 trial looking at patient-reported outcomes and cytopenias in patients with MDS following imetelstat treatment.

Gary J. Schiller, MD, reviews recent data on durable transfusion independence for patients with lower-risk MDS in the IMerge phase 3 study and discusses how transfusion frequency affects patient outcomes.

An expert on myelodysplastic syndrome discusses the impact of mutational status on response in the IMerge phase 3 study.

Findings from 2 Chinese clinical trials of olverembatinib support its addition to The National Comprehensive Cancer Network guidelines for the treatment of patients with chronic myeloid leukemia.

Clinicians review the MEDALIST trial, which evaluated luspatercept in the second-line setting and comment on updated data from MEDALIST that was recently presented at the annual ASH 2023 meeting.

Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.

The phase 3 ASCERTAIN study found that orally administered decitabine and cedazuridine had similar pharmacologic effects compared with intravenously administered decitabine.

An investigational new drug for BSI-082 has been cleared by the FDA for the treatment of hematologic and solid tumors.

Tamoxifen, a selective estrogen receptor modulator, shows potential as a line of treatment in some patients with myeloproliferative neoplasms.

Dr Shadman provides insightful discussion on optimizing outcomes with BTK inhibition in CLL through adverse event mitigation and sustaining treatment in later lines.